Coherus Oncology Valuation Multiples

Coherus Oncology Overview

About Coherus Oncology

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Founded

2010

HQ

Employees

228

Website

coherus.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $54M

EBITDA: ($178M)

EV

$117M

Valuation Multiples

Multiples.vc

Start free trial

Coherus Oncology Financials

Coherus Oncology reported last 12-month revenue of $54M and negative EBITDA of ($178M).

In the same LTM period, Coherus Oncology generated $36M in gross profit, ($178M) in EBITDA losses, and had net loss of ($174M).

Coherus Oncology P&L

In the most recent fiscal year, Coherus Oncology reported revenue of $42M and EBITDA of ($170M).

Coherus Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX

Coherus Oncology Stock Performance

Coherus Oncology has current market cap of $249M, and enterprise value of $117M.

Coherus Oncology's stock price is $1.66.

Coherus Oncology Valuation Multiples

Coherus Oncology trades at 2.2x EV/Revenue multiple, and (0.7x) EV/EBITDA.

Coherus Oncology Financial Valuation Multiples

As of April 11, 2026, Coherus Oncology has market cap of $249M and EV of $117M.

Equity research analysts estimate Coherus Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Coherus Oncology has a P/E ratio of (1.4x).

Coherus Oncology Margins & Growth Rates

Coherus Oncology's revenue in the last 12 month grew by 71%.

Coherus Oncology's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.9M for the same period.

Coherus Oncology's rule of 40 is (101%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Coherus Oncology's rule of X is 49% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Coherus Oncology Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Coherus Oncology M&A Activity

Coherus Oncology acquired XXX companies to date.

Last acquisition by Coherus Oncology was on XXXXXXXX, XXXXX. Coherus Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Coherus Oncology Investment Activity

Coherus Oncology invested in XXX companies to date.

Coherus Oncology made its latest investment on XXXXXXXX, XXXXX. Coherus Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).